Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two years.

Huntington's disease is a rare genetic, autosomal dominant, neurodegenerative disease, caused by CAG repeat expansions in the HTT gene, that is polymorphic on the healthy allele and contains more than ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...